Laura Chico
Stock Analyst at Wedbush
(3.58)
# 851
Out of 5,051 analysts
222
Total ratings
46.1%
Success rate
6.8%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Neutral | $28 → $13 | $12.25 | +6.12% | 10 | Oct 15, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $15 → $11 | $3.80 | +189.47% | 3 | Sep 30, 2025 | |
| PEPG PepGen | Maintains: Outperform | $9 → $8 | $4.53 | +76.60% | 12 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $42 → $44 | $33.18 | +32.61% | 9 | Sep 12, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $9.00 | +100.00% | 3 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $14 | $4.41 | +217.82% | 3 | Aug 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $25.34 | -13.18% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $39.09 | +10.00% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $34.13 | -6.24% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $2.30 | +117.39% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $5.60 | +150.00% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $143.19 | -1.53% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $32.46 | +4.74% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $32.42 | -47.56% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $6.76 | +166.27% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $121.65 | +6.86% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $149.33 | -18.97% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $21.64 | +24.77% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $11.23 | -64.38% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $14.92 | +101.07% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $24.35 | +6.78% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $171.75 | -83.70% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $17.33 | +148.20% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.33 | +125.56% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $20.47 | +41.67% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.16 | +68.27% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $22.55 | +86.25% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.63 | +1,647.42% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $6.24 | -19.87% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $52.52 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.27 | +17.10% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $13.95 | +964.52% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $11.25 | +6,300.00% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $100.39 | +178.91% | 1 | Apr 21, 2017 |
Astria Therapeutics
Oct 15, 2025
Downgrades: Neutral
Price Target: $28 → $13
Current: $12.25
Upside: +6.12%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.80
Upside: +189.47%
PepGen
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.53
Upside: +76.60%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $33.18
Upside: +32.61%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $9.00
Upside: +100.00%
Solid Biosciences
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $4.41
Upside: +217.82%
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $25.34
Upside: -13.18%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $39.09
Upside: +10.00%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $34.13
Upside: -6.24%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.30
Upside: +117.39%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.60
Upside: +150.00%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $143.19
Upside: -1.53%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $32.46
Upside: +4.74%
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $32.42
Upside: -47.56%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $6.76
Upside: +166.27%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $121.65
Upside: +6.86%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $149.33
Upside: -18.97%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $21.64
Upside: +24.77%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $11.23
Upside: -64.38%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.92
Upside: +101.07%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $24.35
Upside: +6.78%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $171.75
Upside: -83.70%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $17.33
Upside: +148.20%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.33
Upside: +125.56%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $20.47
Upside: +41.67%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.16
Upside: +68.27%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $22.55
Upside: +86.25%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.63
Upside: +1,647.42%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $6.24
Upside: -19.87%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $52.52
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.27
Upside: +17.10%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $13.95
Upside: +964.52%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $11.25
Upside: +6,300.00%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $100.39
Upside: +178.91%